MedTrace Logo

Pentoxifylline for Treatment of Resistant Major Depression

NCT05324735 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-09-07

No results posted yet for this study

Summary

A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders. Herein, we aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in the treatment of therapy-resistant depression (TRD) in adult patients with bipolar depression.

Conditions

  • Resistant Major Depression

Interventions

DRUG

Pentoxifylline

All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.

DRUG

Placebo

All participants will receive placebo (orally ingested) twice a day for 12 weeks.

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Talar A Merzamohammad, Pharm. D · Hawler Medical University, College of Pharmacy, Department of Pharmacology and Toxicology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2022-05-04
Completion
2022-06-04

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05324735 on ClinicalTrials.gov